Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › AVTX
SILVERARC CAPITAL MANAGEMENT, LLC position in AVTX
AVALO THERAPEUTICS INC · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 500,402 shares of AVTX (AVALO THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$9.2M, representing 1.08% of its reported portfolio and ranking #30 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed AVTX holdings in 3 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's AVTX position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in AVTX in Q3 2025 at 720,922 shares (US$9.2M). The position peaked in Q4 2025 at 524,436 shares, worth US$9.5M. Across 3 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 500,402 shares valued at US$9.2M. Notable position changes include a 27% trim in Q4 2025 (shares fell 18% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 720.92K | $9.16M | New |
| Q4 2025 | 524.44K | $9.52M | Reduce |
| Q2 2026 | 500.40K | $9.25M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVTX and 13F data
AVTX (AVALO THERAPEUTICS INC) is a Health Care company. 83 other funds we track also report a position in AVTX — the largest reported positions include Deep Track Capital, LP (US$66.7M), Caligan Partners LP (US$58.5M), TCG Crossover Management, LLC (US$55.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVTX
- Deep Track Capital, LP 3.61M sh · $66.71M · Q2 2026
- Caligan Partners LP 3.16M sh · $58.47M · Q2 2026
- TCG Crossover Management, LLC 3.02M sh · $55.76M · Q2 2026
- Affinity Asset Advisors, LLC 2.90M sh · $53.59M · Q2 2026
- Farallon Capital Management 2.50M sh · $46.16M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 2.50M sh · $46.16M · Q2 2026
- Avoro Capital Advisors LLC 2.33M sh · $43.12M · Q2 2026
- BVF INC/IL 2.08M sh · $38.36M · Q2 2026
- Nantahala Capital Management, LLC 1.86M sh · $34.41M · Q2 2026
- Soleus Capital Management, L.P. 1.65M sh · $30.58M · Q2 2026
- BRAIDWELL LP 1.63M sh · $30.11M · Q2 2026
- Logos Global Management LP 1.15M sh · $21.25M · Q2 2026
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held AVTX?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed AVTX holdings in 3 of the last 4 reported quarters, going back to Q3 2025.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in AVTX?
As of Q2 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 500.40K shares of AVTX (AVALO THERAPEUTICS INC), valued at $9.25M, representing 1.08% of its reported portfolio and ranking #30.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling AVTX?
In the latest 13F filing (Q2 2026), SILVERARC CAPITAL MANAGEMENT, LLC newly opened its position in AVTX. The position peaked in Q4 2025 at 524.44K shares.
Which other funds hold AVTX?
Other major institutional holders of AVTX include Deep Track Capital, LP, Caligan Partners LP, TCG Crossover Management, LLC, among 83 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.